Avacta Group, the listed developer of cancer therapies and diagnostics based on its propriety Affimer and pre|CISION platforms, has struck a global distribution agreement with ABCAM.
The deal will see the Wetherby-based life science business sell its recently developed SARS-CoV-2 research ELISA Affimer reagents.
The Affimer reagents can be used in a high performance ELISA laboratory test to detect the SARS-CoV-2 spike protein with high sensitivity and excellent specificity for the spike protein of the original strain of the virus and other dominant variants such as B117 (“Kent” strain) and D614G.
Under the worldwide, non-exclusive distribution agreement, ABCAM – a supplier of high-quality biological reagents and kits – will enable the global research community to access Avacta’s SARS-CoV-2 spike protein Affimer research reagents through its on-line catalogue.
This will allow scientists around the world to perform the ELISA test in their own laboratories and support the global fight against the pandemic.
“We are delighted that we have established a global route to market for the SARS-CoV-2 spike protein Affimer reagents through ABCAM’s dedicated global commercialisation infrastructure,” said Avacta Chief Executive, Dr Alastair Smith.
“As far as we are aware, our spike protein ELISA test is the most sensitive test of its kind and, in ABCAM, we have a world-leading partner capable of maximising the commercial potential of the Affimer® reagents by making them globally available to scientists who are researching into the SARS-CoV-2 coronavirus.”